{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:22:17Z","timestamp":1792027337032,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract\u00a0<\/jats:title><jats:p>Identification of pediatric patients with acute myeloid leukemia (AML) candidates to receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) is still a matter of debate. Currently, transplantation is reserved to patients considered at high risk of relapse based on cytogenetics, molecular biology, and minimal residual disease (MRD) assessment. However, no randomized clinical trial exists in the literature comparing transplantation with other types of consolidation therapy. Here, we provide an up-to-date meta-analysis of studies comparing allo-HSCT in CR1 with chemotherapy alone as a post-remission treatment in high-risk pediatric AML. The literature search strategy identified 10 cohorts from 9 studies performing as-treated analysis. The quantitative synthesis showed improved overall survival (OS) (relative risk, 1.15; 95% confidence interval [CI], 1.06\u20131.24;<jats:italic>P<\/jats:italic>\u2009=\u20090.0006) and disease-free survival (relative risk, 1.31; 95% CI, 1.17\u20131.47;<jats:italic>P<\/jats:italic>\u2009=\u20090.0001) in the allo-HSCT group, with increased relapse rate in the chemotherapy group (relative risk, 1.26; 95% CI, 1.07\u20131.49;<jats:italic>P<\/jats:italic>\u2009=\u20090.006). Sensitivity analysis including prospective studies alone and excluding studies that reported the comparison only on intermediate-risk patients confirmed the benefit of allo-HSCT on OS. Further research should focus on individualizing allo-HSCT indications based on molecular stratification and MRD monitoring.<\/jats:p>","DOI":"10.1007\/s00277-022-04965-x","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T02:02:35Z","timestamp":1661824955000},"page":"2497-2506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis"],"prefix":"10.1007","volume":"101","author":[{"given":"Riccardo","family":"Masetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-3140","authenticated-orcid":false,"given":"Edoardo","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"4965_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","volume":"29","author":"C-H Pui","year":"2011","unstructured":"Pui C-H, Carroll WL, Meshinchi S, Arceci RJ (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29:551\u2013565","journal-title":"J Clin Oncol"},{"key":"4965_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071972","volume":"12","author":"A Lonetti","year":"2020","unstructured":"Lonetti A, Indio V, Laginestra MA, Tarantino G, Chiarini F, Astolfi A et al (2020) Inhibition of methyltransferase dot1l sensitizes to sorafenib treatment aml cells irrespective of mll-rearrangements: a novel therapeutic strategy for pediatric aml. Cancers (Basel) 12:1\u201318","journal-title":"Cancers (Basel)"},{"key":"4965_CR3","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R et al (2015) Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol 33:2949\u20132962","journal-title":"J Clin Oncol"},{"key":"4965_CR4","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2012-03-362608","volume":"120","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, De Bont E et al (2012) Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120:3167\u20133205","journal-title":"Blood"},{"key":"4965_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.12900","volume":"166","author":"H Hasle","year":"2014","unstructured":"Hasle H (2014) A critical review of which children with acute myeloid leukemia need stem cell procedures. Br J Haematol 166:23\u201333","journal-title":"Br J Haematol"},{"key":"4965_CR6","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2010-01-261800","volume":"116","author":"D Niewerth","year":"2010","unstructured":"Niewerth D, Creutzig U, Bierings MB, Kaspers GJL (2010) A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116:2205\u20132214","journal-title":"Blood"},{"key":"4965_CR7","doi-asserted-by":"publisher","unstructured":"Egan G, Chopra Y, Mourad S, Chiang KY, Hitzler J (2021) Treatment of acute myeloid leukemia in children: a practical perspective. Pediatr. Blood Cancer 68. https:\/\/doi.org\/10.1002\/pbc.28979.","DOI":"10.1002\/pbc.28979"},{"key":"4965_CR8","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA - J Am Med Assoc 301:2349\u20132361","journal-title":"JAMA - J Am Med Assoc"},{"key":"4965_CR9","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.3390\/jcm10173790","volume":"10","author":"M Algeri","year":"2021","unstructured":"Algeri M, Merli P, Locatelli F, Pagliara D (2021) The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia. J Clin Med 10:3790. https:\/\/doi.org\/10.3390\/jcm10173790","journal-title":"J Clin Med"},{"key":"4965_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/sj.bmt.1703528","volume":"29","author":"M Bleakley","year":"2002","unstructured":"Bleakley M, Lau L, Shaw PJ, Kaufman A (2002) Bone marrow transplantation for pediatric AML in first remision: a systematic review and meta-analysis. Bone Marrow Transplant 29:843\u2013852","journal-title":"Bone Marrow Transplant"},{"key":"4965_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1046\/j.1365-2141.2003.04418.x","volume":"122","author":"SO Lie","year":"2003","unstructured":"Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L et al (2003) Treatment stratification based on initial in vivo response in acute myeloid leukemia in children without Down\u2019s syndrome: results of NOPHO-AML trials. Br J Haematol 122:217\u2013225","journal-title":"Br J Haematol"},{"key":"4965_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-019-00502-2","volume":"14","author":"P Merli","year":"2019","unstructured":"Merli P, Algeri M, Del Bufalo F, Locatelli F (2019) Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Curr Hematol Malig Rep 14:94\u2013105","journal-title":"Curr Hematol Malig Rep"},{"key":"4965_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1399-3046.2008.00997.x","volume":"13","author":"D-H Lee","year":"2009","unstructured":"Lee D-H, Kwon Y-J, Lim J, Kim Y, Han K, Chung N-G et al (2009) Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatr Transplant 13:210\u2013216","journal-title":"Pediatr Transplant"},{"key":"4965_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.bbmt.2007.01.073","volume":"13","author":"J Moore","year":"2007","unstructured":"Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J et al (2007) Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 13:601\u2013607","journal-title":"Biol Blood Marrow Transplant"},{"key":"4965_CR15","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1200\/JCO.2007.13.5244","volume":"26","author":"JT Horan","year":"2008","unstructured":"Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y et al (2008) Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children\u2019s Oncology Group. J Clin Oncol 26:5797\u20135801","journal-title":"J Clin Oncol"},{"key":"4965_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA et al (2018) The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 24:103\u2013112","journal-title":"Nat Med"},{"key":"4965_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021011694","volume":"138","author":"JE Rubnitz","year":"2021","unstructured":"Rubnitz JE, Kaspers GJL (2021) How I treat pediatric acute myeloid leukemia. Blood 138:1009\u20131018","journal-title":"Blood"},{"key":"4965_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","volume":"39","author":"SE Conneely","year":"2020","unstructured":"Conneely SE, Rau RE (2020) The genomics of acute myeloid leukemia in children. Cancer Metastasis Rev 39:189\u2013209","journal-title":"Cancer Metastasis Rev"},{"key":"4965_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1155\/2019\/3408318","volume":"2019","author":"A Lonetti","year":"2019","unstructured":"Lonetti A, Iacobucci I, Masetti R (2019) Successes and challenges for diagnosis and therapy of acute leukemia. J Oncol 2019:2\u20133","journal-title":"J Oncol"},{"key":"4965_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.15725","volume":"184","author":"R Masetti","year":"2019","unstructured":"Masetti R, Bertuccio SN, Pession A, Locatelli F (2019) CBFA2T3-GLIS2-positive acute myeloid leukemia. A peculiar pediatric entity. Br J Haematol 184:337\u2013347","journal-title":"Br J Haematol"},{"key":"4965_CR21","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"4965_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"4965_CR23","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0[online]. The Cochrane Collaboration 2011 Available from. www.cochrane-handbook.org"},{"key":"4965_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP et al (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12:1495\u20131499","journal-title":"Int J Surg"},{"issue":"180","key":"4965_CR25","first-page":"e1","volume":"27","author":"D Zama","year":"2021","unstructured":"Zama D, Gori D, Muratore E, Leardini D, Rallo F, Turroni S et al (2021) Enteral versus parenteral nutrition as nutritional support after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transplant Cell Ther 27(180):e1-180.e8","journal-title":"Transplant Cell Ther"},{"key":"4965_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","volume":"122","author":"A Pession","year":"2013","unstructured":"Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F et al (2013) Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 122:170\u2013178","journal-title":"Blood"},{"key":"4965_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3324\/haematol.2011.051714","volume":"97","author":"JH Klusmann","year":"2012","unstructured":"Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M et al (2012) The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 97:21\u201329","journal-title":"Haematologica"},{"key":"4965_CR28","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","volume":"27","author":"I Tsukimoto","year":"2009","unstructured":"Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M et al (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese childhood AML cooperative study group. J Clin Oncol 27:4007\u20134013","journal-title":"J Clin Oncol"},{"key":"4965_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","volume":"11","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncol 11:543\u2013552","journal-title":"Lancet Oncol"},{"key":"4965_CR30","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC et al (2014) Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase iII Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol 32:3021\u20133032","journal-title":"J Clin Oncol"},{"key":"4965_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.27875","volume":"66","author":"N Hyakuna","year":"2019","unstructured":"Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M et al (2019) Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Pediatr Blood Cancer 66:1\u20139","journal-title":"Pediatr Blood Cancer"},{"key":"4965_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/pbc.24739","volume":"61","author":"MJ Kelly","year":"2014","unstructured":"Kelly MJ, Horan JT, Alonzo TA, Eapen M, Gerbing RB, He W et al (2014) Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatr Blood Cancer 61:269\u2013275","journal-title":"Pediatr Blood Cancer"},{"key":"4965_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/children8020109","volume":"8","author":"JM Lee","year":"2021","unstructured":"Lee JM, Yang EJ, Park KM, Lee YH, Chueh H, Hah JO et al (2021) Treatment outcomes of pediatric acute myeloid leukemia in the Yeungnam region: a multicenter retrospective study of the study alliance of Yeungnam pediatric hematology\u2013oncology (sayph). Children 8:109. https:\/\/doi.org\/10.3390\/children8020109","journal-title":"Children"},{"key":"4965_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MPH.0000000000001751","volume":"42","author":"Y Dufort","year":"2020","unstructured":"Dufort Y, Alvarez G, Castiglioni M, Pag\u00e9s C, Incoronato A, Simon E, Zuccolo S et al (2020) Treatment of childhood acute myeloid leukemia in uruguay: results of 2 consecutive protocols over 20 years. J Pediatr Hematol Oncol 42:359\u2013366","journal-title":"J Pediatr Hematol Oncol"},{"key":"4965_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornh\u00e4user M, Juliusson G et al (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 9:579\u2013590","journal-title":"Nat Rev Clin Oncol"},{"key":"4965_CR36","doi-asserted-by":"crossref","unstructured":"Locatelli F, Masetti R, Rondelli R, Zecca M, Fagioli F, Rovelli A et al (2015) Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002 \/ 01 study This article has been corrected since Advance Online Publication and an erratum is also printed in. Bone Marrow Transplant 181\u2013188","DOI":"10.1038\/bmt.2014.246"},{"key":"4965_CR37","doi-asserted-by":"publisher","first-page":"438","DOI":"10.5694\/j.1326-5377.2003.tb05627.x","volume":"179","author":"SR Heritier","year":"2003","unstructured":"Heritier SR, Gebski VJ, Keech AC (2003) Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 179:438\u2013440","journal-title":"Med J Aust"},{"key":"4965_CR38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/ng.3709","volume":"48","author":"ZJ Faber","year":"2016","unstructured":"Faber ZJ, Chen X, Larson Gedman A, Boggs K, Cheng J, Ma J et al (2016) The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet 48:1551\u20131556. https:\/\/doi.org\/10.1038\/ng.3709","journal-title":"Nat Genet"},{"key":"4965_CR39","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/sj.leu.2403870","volume":"19","author":"BF Goemans","year":"2005","unstructured":"Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S et al (2005) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19:1536\u20131542","journal-title":"Leukemia"},{"key":"4965_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/blood-2018-03-837781","volume":"132","author":"R Itzykson","year":"2018","unstructured":"Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M et al (2018) Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood 132:187\u2013196","journal-title":"Blood"},{"key":"4965_CR41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/leu.2013.339","volume":"28","author":"E Manara","year":"2014","unstructured":"Manara E, Bisio V, Masetti R, Beqiri V, Rondelli R, Menna G et al (2014) Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002\/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 28:1132\u20131134","journal-title":"Leukemia"},{"key":"4965_CR42","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","volume":"25","author":"K Tarlock","year":"2019","unstructured":"Tarlock K, Alonzo TA, Wang Y-C, Gerbing RB, Ries R, Loken MR et al (2019) Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res 25:5038\u20135048","journal-title":"Clin Cancer Res"},{"key":"4965_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12885-020-07043-5","volume":"20","author":"G-H Hu","year":"2020","unstructured":"Hu G-H, Cheng Y-F, Lu A-D, Wang Y, Zuo Y-X, Yan C-H et al (2020) Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. BMC Cancer 20:553","journal-title":"BMC Cancer"},{"key":"4965_CR44","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1182\/blood-2010-12-328302","volume":"117","author":"EA Coenen","year":"2011","unstructured":"Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al (2011) Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23\/MLL-rearranged AML patients: results of an international study. Blood 117:7102\u20137111","journal-title":"Blood"},{"key":"4965_CR45","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","volume":"114","author":"BV Balgobind","year":"2009","unstructured":"Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al (2009) Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114:2489\u20132496","journal-title":"Blood"},{"key":"4965_CR46","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"4965_CR47","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA et al (2020) Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 105:1507\u20131516","journal-title":"Haematologica"},{"key":"4965_CR48","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1182\/blood-2008-10-184747","volume":"113","author":"PA Ho","year":"2009","unstructured":"Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C et al (2009) Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children\u2019s Oncology Group. Blood 113:6558\u20136566","journal-title":"Blood"},{"key":"4965_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hon.904","volume":"27","author":"R Rau","year":"2009","unstructured":"Rau R, Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukemia: towards definition of a new leukemia entity. Hematol Oncol 27:171\u2013181","journal-title":"Hematol Oncol"},{"key":"4965_CR50","doi-asserted-by":"crossref","unstructured":"MRD-AML-BFM Study Group L, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E et al (2006) Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 24:3686\u20133692","DOI":"10.1200\/JCO.2005.05.4312"},{"key":"4965_CR51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) Update measurable residual disease in acute myeloid leukemia: European LeukemiaNet Working Party Consensus Document. Blood. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"key":"4965_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.14523","volume":"177","author":"B Buldini","year":"2017","unstructured":"Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C et al (2017) Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukemia treated according to the AIEOP-AML 2002\/01 study protocol. Br J Haematol 177:116\u2013126","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04965-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T08:35:39Z","timestamp":1700987739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04965-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4965"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04965-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}